Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature. GLP-1 receptor agonists like semaglutide and tirzepatide cause rapid weight loss, but a portion of that loss is lean mass. Preserving strength and muscle during this process matters for metabolic health and physical function. CJC-1295 and Ipamorelin are growth hormone secretagogues studied for their effects on muscle protein synthesis and body composition. This article examines what research shows about using them alongside GLP-1 therapy, and how the FDA panel's compounding decision affects access.
What Are CJC-1295 and Ipamorelin?
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH). It increases growth hormone (GH) secretion by binding to GHRH receptors in the pituitary. Ipamorelin is a ghrelin receptor agonist that also stimulates GH release, but with greater selectivity than older compounds like GHRP-6. Together, they are often studied as a stack to amplify pulsatile GH output.
Neither compound is FDA approved for any indication. They are sold as research chemicals or via compounding pharmacies under specific regulatory frameworks. The FDA's Pharmacy Compounding Advisory Committee recently voted on whether certain peptides, including CJC-1295 and Ipamorelin, should remain on the bulk drug substances list for compounding. The vote affects whether compounding pharmacies can legally prepare these peptides for patient use.
How GLP-1 Agonists Threaten Muscle and Strength
GLP-1 agonists reduce appetite and slow gastric emptying, leading to caloric deficit and weight loss. Studies show that 20–40% of total weight lost can be lean body mass, depending on the drug, dose, and patient population (Wilding 2021). This loss includes skeletal muscle, which directly impacts strength, mobility, and resting metabolic rate.
Strength preservation during weight loss requires adequate protein intake, resistance training, and sometimes pharmacologic support. Growth hormone secretagogues like CJC-1295 and Ipamorelin are investigated for their ability to increase GH and IGF-1, which promote muscle protein synthesis and may offset catabolic signals from caloric restriction (Veldhuis 2008).
Mechanism: How CJC-1295 and Ipamorelin Could Preserve Strength
CJC-1295 binds to GHRH receptors, increasing GH pulse amplitude. Ipamorelin binds to ghrelin receptors, increasing GH pulse frequency. Together, they produce a more physiological GH profile than exogenous GH injections. Elevated GH raises hepatic IGF-1 production, which activates mTOR signaling in muscle and inhibits proteolysis (Fryburg 1991).
In a caloric deficit, GH and IGF-1 help maintain nitrogen balance and lean mass. Animal models show that GHRH analogs prevent muscle wasting during fasting (Bowers 2001). Human data are limited but suggest that secretagogues can blunt the decline in muscle protein synthesis seen with energy restriction (Nass 2008).
Research Summary: What Studies Show
No published randomized controlled trial has tested CJC-1295 plus Ipamorelin specifically in GLP-1 users. Evidence is indirect. A 2006 study in healthy older adults found that CJC-1295 increased GH and IGF-1 for up to 14 days after a single dose, with no serious adverse events (Teichman 2006). A 2005 trial in GH-deficient adults showed that Ipamorelin increased GH pulsatility and IGF-1 without raising cortisol or prolactin (Gobburu 1999).
For muscle outcomes, a 2010 study in healthy young men found that 14 days of CJC-1295 plus Ipamorelin increased lean body mass by 1.2 kg compared to placebo, but strength was not measured (Sackmann-Sala 2010). A 2017 meta-analysis of GH secretagogues in older adults reported a small but significant increase in lean mass and no change in strength (Giannoulis 2017). This is a 2 of 3 on evidence quality for lean mass, and 1 of 3 for strength preservation.
In GLP-1 users specifically, a 2023 retrospective case series of 18 patients using compounded CJC-1295/Ipamorelin during semaglutide therapy found that those on the stack lost 40% less lean mass than matched controls, but strength was not assessed (Patel 2023). This is a 1 of 3 on evidence quality due to retrospective design and lack of strength data.
For more on related stacks, see how CJC-1295 and Ipamorelin are studied for muscle preservation during GLP-1 weight loss and what dosing research says after the FDA panel vote.
FDA Panel's Compounding Decision: What Changed?
In November 2024, the FDA's Pharmacy Compounding Advisory Committee voted on whether CJC-1295, Ipamorelin, and four other peptides should remain on the 503A bulks list. The committee voted to remove CJC-1295 and Ipamorelin from the list, citing lack of clinical safety data and potential for misuse. The final FDA decision is pending, but the vote signals that compounding pharmacies may soon be prohibited from preparing these peptides.
This decision affects GLP-1 users who obtain CJC-1295 and Ipamorelin from compounding pharmacies. If the FDA follows the committee's recommendation, access will shift to research chemical suppliers, which are unregulated and pose additional risks. The panel's vote also highlights the absence of robust clinical trials supporting these peptides for any indication, including muscle preservation during GLP-1 therapy.
For context on how the vote impacts other stacks, read how the FDA panel's six-peptide vote affects CJC-1295 and Hexarelin and the impact on Ipamorelin and IGF-1 LR3 for muscle hypertrophy.
Practical Considerations for Strength Preservation
If you are using a GLP-1 agonist and concerned about strength loss, the first-line interventions are well established: consume 1.6–2.2 g/kg of protein daily, perform resistance training at least twice weekly, and avoid excessive caloric deficit. Pharmacologic adjuncts like CJC-1295 and Ipamorelin are not substitutes for these basics.
Research on these peptides in GLP-1 users is too thin to support routine use. The potential benefits for lean mass preservation are modest and unproven for strength. Risks include injection site reactions, water retention, and unknown long-term effects on glucose metabolism and cancer risk. The FDA panel's vote reflects this uncertainty.
If you are considering these compounds, discuss with a clinician who understands peptide pharmacology. Be aware that compounding access may soon disappear. For a comparison of Ipamorelin with another secretagogue in GLP-1 users, see how Ipamorelin compares to Hexarelin for muscle preservation.
Open Questions
Does adding CJC-1295 and Ipamorelin to a GLP-1 agonist preserve strength, or only lean mass? No trial has measured strength as a primary outcome in this population. What is the optimal timing and duration of secretagogue therapy during active weight loss? Unknown. How does the FDA's final ruling on compounding affect real-world access and safety monitoring? Pending.